Form 4: Zura Bio Director Eisner Granted 37,812 Stock Options

Zura Bio Ltd. Director Mark Eisner was granted 37,812 share options with an exercise price of $6.53, vesting over one year.

Summary

• Mark Eisner, a Director of Zura Bio Ltd. (ZURA), was granted 37,812 share options.
• The options have an exercise price of $6.53 per share.
• The grant date for these options was February 21, 2026.
• The options vest in twelve substantially equal monthly installments over a one-year period, commencing February 21, 2026.
• Any remaining unvested portion of the option award will vest the day immediately preceding the next annual meeting of shareholders following the grant date, contingent on Mr. Eisner's continued service.
• The options have an expiration date of February 21, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a standard compensation practice that aligns a director's interests with the company's long-term performance, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to Director Mark Eisner aligns his interests with those of shareholders, incentivizing long-term performance and value creation for Zura Bio Ltd.

Future Outlook

The options are subject to a vesting schedule over a one-year period from February 21, 2026, with a final vesting event potentially occurring before the next annual meeting of shareholders, indicating future milestones related to the director's compensation.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a performance incentive and a means to align management and board interests with long-term shareholder value. This transaction is a routine compensation event for a director.

Comparison to Industry Standards

• Option grants to directors are a standard component of executive and board compensation across various industries, including biotech, to incentivize long-term commitment and performance.
• The vesting schedule over one year is typical for such grants, ensuring continued service and alignment with company objectives.

Related Party Transactions

• The grant of stock options to Director Mark Eisner constitutes an insider transaction, which is a common form of compensation for company leadership.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will vest in twelve substantially equal monthly installments over a one-year period from February 21, 2026.
• Any remaining unvested portion will vest the day before the next annual meeting of shareholders following the grant date, subject to continued service.

Key Dates

Keywords

Zura Bio, ZURA, stock options, director compensation, insider transaction, Form 4